Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
Immunome, Inc. (Nasdaq: IMNM) has announced that it will present updated results from the RINGSIDE Phase 2 clinical trial of AL102 for the treatment of desmoid tumors at the European Society of Medical Oncology (ESMO) Congress in Barcelona, September 13-17, 2024. The presentation will be in poster format, titled 'Updated Results of the RINGSIDE Phase 2 Trial and Open-Label Extension of AL102 for the Treatment of Desmoid Tumors' (Abstract #1766P), presented by Dr. Bernd Kasper on September 14, 2024.
Notably, enrollment in the Phase 3 portion of RINGSIDE was completed in February 2024, with topline data expected in the second half of 2025. The poster will be available on Immunome's website after the presentation.
Immunome, Inc. (Nasdaq: IMNM) ha annunciato che presenterà risultati aggiornati del trial clinico RINGSIDE di Fase 2 di AL102 per il trattamento dei tumori desmoidi al Congresso della Società Europea di Oncologia Medica (ESMO) a Barcellona, dal 13 al 17 settembre 2024. La presentazione avverrà in formato poster, intitolata 'Risultati Aggiornati del Trial RINGSIDE di Fase 2 e Estensione in Etichetta Aperta di AL102 per il Trattamento dei Tumori Desmoidi' (Abstract #1766P), presentata dal Dott. Bernd Kasper il 14 settembre 2024.
È importante notare che l'arruolamento nella parte di Fase 3 di RINGSIDE è stato completato a febbraio 2024, con dati preliminari attesi nella seconda metà del 2025. Il poster sarà disponibile sul sito web di Immunome dopo la presentazione.
Immunome, Inc. (Nasdaq: IMNM) ha anunciado que presentará resultados actualizados del ensayo clínico de Fase 2 RINGSIDE de AL102 para el tratamiento de tumores desmoides en el Congreso de la Sociedad Europea de Oncología Médica (ESMO) en Barcelona, del 13 al 17 de septiembre de 2024. La presentación será en formato de póster, titulado 'Resultados Actualizados del Ensayo RINGSIDE de Fase 2 y Extensión Abierta de AL102 para el Tratamiento de Tumores Desmoides' (Resumen #1766P), presentada por el Dr. Bernd Kasper el 14 de septiembre de 2024.
Es notable que la inscripción en la parte de Fase 3 de RINGSIDE se completó en febrero de 2024, con datos preliminares esperados en la segunda mitad de 2025. El póster estará disponible en el sitio web de Immunome después de la presentación.
Immunome, Inc. (Nasdaq: IMNM)은 AL102의 desmoid 종양 치료를 위한 RINGSIDE 2단계 임상 시험의 업데이트된 결과를 2024년 9월 13-17일 바르셀로나에서 열리는 유럽 종양학회(ESMO) 국제 컨그레스에서 발표할 것이라고 발표했습니다. 발표는 'Desmoid 종양 치료를 위한 AL102의 RINGSIDE 2단계 시험 및 공개 연장 업데이트 결과' (초록 #1766P)라는 제목의 포스터 형식으로, 2024년 9월 14일에 Dr. Bernd Kasper가 발표할 예정입니다.
특히, RINGSIDE의 3단계 부분에 대한 모집이 2024년 2월에 완료되었으며, 주요 데이터는 2025년 하반기에 예상됩니다. 발표 후 Immunome의 웹사이트에서 포스터를 확인할 수 있습니다.
Immunome, Inc. (Nasdaq: IMNM) a annoncé qu'elle présentera des résultats mis à jour de l'
Il convient de noter que l'enrôlement dans la partie Phase 3 de RINGSIDE a été complété en février 2024, avec des données préliminaires attendues dans la seconde moitié de 2025. Le poster sera disponible sur le site Web d'Immunome après la présentation.
Immunome, Inc. (Nasdaq: IMNM) hat angekündigt, dass aktualisierte Ergebnisse aus der RINGSIDE Phase 2-Studie zu AL102 zur Behandlung von Desmoid-Tumoren auf dem Europäischen Kongress für Onkologie (ESMO) in Barcelona vom 13. bis 17. September 2024 präsentiert werden. Die Präsentation wird im Posterformat mit dem Titel 'Aktualisierte Ergebnisse der RINGSIDE Phase 2-Studie und der offenen Erweiterung von AL102 zur Behandlung von Desmoid-Tumoren' (Abstract #1766P) am 14. September 2024 von Dr. Bernd Kasper gehalten.
Bemerkenswert ist, dass die Rekrutierung für die Phase 3 des RINGSIDE im Februar 2024 abgeschlossen wurde und die wichtigsten Daten in der zweiten Hälfte des Jahres 2025 erwartet werden. Das Poster wird nach der Präsentation auf der Website von Immunome verfügbar sein.
- Completion of enrollment for Phase 3 RINGSIDE trial in February 2024
- Upcoming presentation of updated Phase 2 results at ESMO Congress 2024
- Expected topline data from Phase 3 trial in second half of 2025
- None.
Enrollment in the Phase 3 portion of RINGSIDE was completed in February 2024, and Immunome expects to report topline data from that trial in the second half of 2025.
Following the presentation, a copy of the poster will be made available in the “Events & Presentations” portion of Immunome’s website.
Poster Presentation Details:
Title: Updated Results of the RINGSIDE Phase 2 Trial and Open-Label Extension of AL102 for the Treatment of Desmoid Tumors (Abstract #1766P)
Presenter: Bernd Kasper, MD, PhD, Mannheim Cancer Center at the Mannheim University Medical Center,
Date: September 14, 2024
About Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugates (ADCs). In addition to a portfolio of discovery-stage ADCs, our pipeline includes AL102, a gamma secretase inhibitor currently in a Phase 3 trial for treatment of desmoid tumors, as well as IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted radioligand, both of which are the subject of INDs expected to be submitted in the first quarter of 2025. For more information, visit www.immunome.com.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We use words such as “will,” “expects” and similar expressions to identify forward-looking statements. These forward-looking statements include, but are not limited to, Immunome’s expected timing for providing topline data for the Phase 3 RINGSIDE Part B trial and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. These forward-looking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risk that Immunome will not be able to realize the benefits of its strategic transactions; the risk that regulatory approvals for Immunome’s product candidates are not obtained, are delayed or are subject to unanticipated conditions; the risk that pre-clinical data may not be predictive of clinical data; the risk that Immunome’s product candidates fail to achieve their intended endpoints; and other risks and uncertainties indicated from time to time described in Immunome’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 12, 2024, and in Immunome’s other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240913809373/en/
Immunome Contact:
Max Rosett
Chief Financial Officer
investors@immunome.com
Source: Immunome, Inc.
FAQ
What is Immunome (IMNM) presenting at the ESMO Congress 2024?
When will Immunome (IMNM) report topline data from the Phase 3 RINGSIDE trial?
Who is presenting the RINGSIDE Phase 2 trial results for Immunome (IMNM) at ESMO 2024?
When was enrollment completed for Immunome's (IMNM) Phase 3 RINGSIDE trial?
